Get a glimpse into our company and investor data—powered by the PitchBook Platform
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology, and neuroscience. The majority of sales come from international markets with the United States representing close to one third of its sales.
You’re viewing a free company profile from the PitchBook Platform. To explore AstraZeneca’s full profile, request a free trial.
52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
---|---|---|---|---|---|
$1.41 - $101.47 | $124B | $94.89 | $1.61 | 2.18M | 1.31B |
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
---|---|---|---|---|
Enterprise Value | 132,068,052 | 112,692,471 | 101,489,615 | 84,488,797 |
Revenue | 24,137,000 | 22,090,000 | 22,465,000 | 23,002,000 |
EBITDA | 5,583,000 | 5,532,000 | 5,364,000 | 6,542,000 |
Net Income | 2,056,000 | 2,155,000 | 3,001,000 | 3,499,000 |
Total Assets | 58,906,000 | 60,651,000 | 63,354,000 | 62,526,000 |
Total Debt | 18,158,000 | 19,113,000 | 17,807,000 | 16,808,000 |
Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
---|
This information is reserved for PitchBook Platform users. To explore AstraZeneca‘s full profile, request access.
Request full access to PitchBookCompany Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Novartis | Corporate Backed or Acquired | Basel, Switzerland | 000000 | 000000000000 | ||
00000 & 00. | Corporation | Kenilworth, NJ | 00000 | |||
000000000000000 | Corporation | Brentford, United Kingdom | 000000 | 00000000000 | ||
00000000 | Corporate Backed or Acquired | Dublin, Ireland | 0000 | 000000&0 | ||
000000 00000 | Corporation | Mumbai, India | 0000 |
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 000000 000 | 22-Aug-2019 | 000000000 00000 00 | 0000 | Buildings and Property | |
000 000000000000 | 12-Jun-2019 | 00000 00000 00 | 00000 | Biotechnology | |
000000 000000 | 23-Oct-2018 | 000000000 00000000 | 000.00 | Biotechnology | |
00000000 | 05-Sep-2018 | 00000 00000 00 | 0000 | Drug Delivery | 0000000 00000 00.0 |
Circassia Pharmaceuticals | 18-Jul-2018 | PIPE | 000.00 | Distributors/Wholesale |
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
0000000, 0000000 0 | 16-Dec-2015 | 000000000 00000 00 | Completed |
|
|
0000000 0000000000 | 23-Mar-2010 | 0000 | 00.00 | Completed |
|
0000000 0000000000 | 29-Sep-2009 | 0000 | 000 | Completed |
|
0000000 0000000000 | 12-Feb-2009 | 0000 | 00.00 | Completed |
|
KuDOS Pharmaceuticals | 31-Jan-2006 | Merger/Acquisition | 00000 | Completed |
Company Name | Industry | Location | Founded |
---|---|---|---|
Acerta Pharma | Drug Discovery | Oss, Netherlands | 2012 |
00 000000 | Drug Discovery | Coppell, TX | 0000 |
00000 000000000000 | Therapeutic Devices | Redwood City, CA | 0000 |
0000 00000000 | Biotechnology | Waltham, MA | 0000 |
00000000000 000000 | Corporate Pension | Södertälje, Sweden | 0000 |
35 Former Executives
You’re viewing 5 of 68 executives. Get the full list »Name | Representing | Role | Since | Contact Info |
---|---|---|---|---|
000000è00 000000 00.0 | Self | Board Member | 000 0000 | |
000000 000000000 | Self | Board Member | 000 0000 | |
0000 000000000 | Self | Non-Executive Chairman of the Board | 000 0000 | |
0000 0000000 | AstraZeneca | Chief Financial Officer & Board Member | 000 0000 | |
000000 0000000000 | Self | Board Member | 000 0000 |
8 Former Board Members
You’re viewing 5 of 17 board members. Get the full list »